Evaluation of the Role of High-mobility Group Box 1 Protein in Patients With Keloids: A Case Control Study.
CONCLUSIONS: High-mobility group box 1 was found to be elevated in patients with keloids compared with their controls, suggesting its role in excessive scarring and the role of its antagonists in therapy. PMID: 31184592 [PubMed - as supplied by publisher]
Condition: Scar Keloid Interventions: Drug: Triamcinolone; Drug: Lidocaine; Drug: Botulinum toxin A Sponsor: Kaohsiung Medical University Recruiting
CONCLUSION Combination keloid therapy using fractional lasers, superficial cryotherapy, and intralesional triamcinolone injection is safe and more effective than individual monotherapies.
ConclusionThermomechanical drug delivery of TAC and 5-FU is safe and effective. This is a promising option for the treatment of keloid scars, particularly in the pediatric population.
Keloids are exuberant scars which extend beyond the borders of the inciting cutaneous injury, they can be disfiguring, pruritic and/or painful and can cause significant impairment of quality of life (QoL). However, little research has been done to assess the burden of keloids on QoL. Our aim was to assess how severely keloids affect QoL and identify whether symptomatology (pain, itch) was associated with the severity of QoL impairment, using patient-reported measures of symptoms and quality of life.
Keloid scars are a result of aberrant would healing due to inflammation or skin trauma that can cause pruritus, contractures and pain. Recent literature suggests a potential association between atopy and keloids. Thus, the primary goal of this study was to assess the association between keloids and atopic dermatitis in a diverse patient population. EPIC was utilized to collect anonymous, aggregate-level data on patients 18 years or greater seen at the Johns Hopkins Hospital System (JHHS) from 4/4/2013 to 12/19/18.
Cutaneous injury can ignite excessive fibroproliferative growth that results in keloid formation. Keloids are associated with significant morbidity related to disfigurement and/or symptoms (e.g. pain, pruritus). First ‐line treatment of formed keloids involves topical or intralesional steroids. Recurrent or resistant keloids are managed by surgical excision or cryotherapy, followed by steroidal application or adjuvant irradiation. While adjuvant irradiation appears to be most efficacious, alternative therapeuti c options are needed for patients without access to radiation centers. Botulinum Toxin A (BTA) appears to have ...
In conclusion POSAS is a reliable and valid scar assessment tool. The factors influencing patient- and observer-reported scar quality differed, and better understanding of this may improve treatment and hence patient-reported scar quality. PMID: 30380964 [PubMed - as supplied by publisher]
Keloids and hypertrophic scars are common benign disorder [1,2]. They result from burns, trauma, surgery, infections like acne and folliculitis . These scars are mainly consist of abnormal deposits of collagen in the scar tissue and result in the significant clinical problem like pain, itching and a deformed look [1,4].